Uveal melanoma: From diagnosis to treatment and the science in between.

Cancer 2016 08 15;122(15):2299-312. Epub 2016 Mar 15.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Melanomas of the choroid, ciliary body, and iris of the eye are collectively known as uveal melanomas. These cancers represent 5% of all melanoma diagnoses in the United States, and their age-adjusted risk is 5 per 1 million population. These less frequent melanomas are dissimilar to their more common cutaneous melanoma relative, with differing risk factors, primary treatment, anatomic spread, molecular changes, and responses to systemic therapy. Once uveal melanoma becomes metastatic, therapy options are limited and are often extrapolated from cutaneous melanoma therapies despite the routine exclusion of patients with uveal melanoma from clinical trials. Clinical trials directed at uveal melanoma have been completed or are in progress, and data from these well designed investigations will help guide future directions in this orphan disease. Cancer 2016;122:2299-2312. © 2016 American Cancer Society.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29727DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567680PMC
August 2016
41 Reads

Publication Analysis

Top Keywords

uveal melanoma
16
clinical trials
8
cutaneous melanoma
8
melanoma
6
uveal
5
options limited
4
therapy options
4
limited extrapolated
4
metastatic therapy
4
melanoma therapies
4
routine exclusion
4
despite routine
4
therapies despite
4
melanoma metastatic
4
extrapolated cutaneous
4
responses systemic
4
factors primary
4
risk factors
4
differing risk
4
relative differing
4

Similar Publications